Trial Profile
A Phase I Trial of Single Agent Trametinib (GSK1120212) in Advanced Cancer Patients With Hepatic Dysfunction
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Gastrointestinal cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 03 Nov 2023 Planned End Date changed from 31 Jul 2023 to 1 Nov 2024.
- 03 Nov 2023 Planned End Date changed from 31 Jul 2023 to 1 Nov 2024.
- 12 Aug 2022 Planned End Date changed from 31 Jul 2022 to 31 Jul 2023.